Combinations of Lysostaphin with β-Lactams Are Synergistic against Oxacillin-Resistant Staphylococcus epidermidis
Open Access
- 1 June 2002
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 46 (6) , 2017-2020
- https://doi.org/10.1128/aac.46.6.2017-2020.2002
Abstract
Oxacillin-resistant Staphylococcus aureus is rapidly killed by the endopeptidase lysostaphin, and the addition of β-lactam antibiotics provides synergistic killing. We investigated the possibility that β-lactams given in combination with lysostaphin would improve the activity of lysostaphin against oxacillin-resistant Staphylococcus epidermidis (ORSE), which is normally less susceptible to lysostaphin. Checkerboard synergy testing was performed for lysostaphin given in combination with oxacillin against 10 ORSE isolates for which the lysostaphin MICs were ≥ 8 μg/ml. The fractional inhibitory concentration index ranged from 0.0234 to 0.2656, indicating synergy, which was confirmed in growth curve experiments. In the rabbit model of experimental aortic valve endocarditis using an ORSE strain, the combination of lysostaphin and nafcillin was as effective as vancomycin alone and significantly better than lysostaphin or nafcillin alone. We conclude that β-lactam antibiotics given in combination with lysostaphin are synergistic against many strains of ORSE.Keywords
This publication has 36 references indexed in Scilit:
- Mechanism and Suppression of Lysostaphin Resistance in Oxacillin-ResistantStaphylococcus aureusAntimicrobial Agents and Chemotherapy, 2001
- Increased oxacillin activity associated with glycopeptides in coagulase-negative staphylococciEuropean Journal of Clinical Microbiology & Infectious Diseases, 1998
- Lif, the lysostaphin immunity factor, complements FemB in staphylococcal peptidoglycan interpeptide bridge formationFEMS Microbiology Letters, 1997
- Staphylococcal Peptidoglycan Interpeptide Bridge Biosynthesis: A Novel Antistaphylococcal Target?Microbial Drug Resistance, 1996
- Antimicrobial susceptibility of coagulase-negative staphylococciAntimicrobial Agents and Chemotherapy, 1994
- Lysostaphin: Use of a Recombinant Bactericidal Enzyme as a Mastitis TherapeuticJournal of Dairy Science, 1991
- Imipenem therapy of experimental Staphylococcus epidermidis endocarditisAntimicrobial Agents and Chemotherapy, 1986
- Systemic Lysostaphin in Man — Apparent Antimicrobial Activity in a Neutropenic PatientNew England Journal of Medicine, 1974
- Lysostaphin: Model for a Specific Enzymatic Approach to Infectious DiseasePublished by Springer Nature ,1972
- THERAPEUTIC ACTIVITY OF LYSOSTAPHIN IN EXPERIMENTAL STAPHYLOCOCCAL INFECTIONSCanadian Journal of Microbiology, 1967